Menu
Back to Journals » Cancer Management and Research » Volume 12
Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial
Authors Zhan M, Zheng H, Yang Y, He Z, Xu T, Li Q
Received 13 October 2020
Accepted for publication 6 December 2020
Published 16 December 2020 Volume 2020:12 Pages 12919—12926
DOI https://doi.org/10.2147/CMAR.S283169
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Chien-Feng Li
Mei Zhan,1– 3 Hanrui Zheng,1– 3 Yu Yang,2,4 Zhiyao He,1 Ting Xu,1,3 Qiu Li2,4
1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, People’s Republic of China; 2West China Biomedical Big Data Center, Sichuan University, Chengdu, People’s Republic of China; 3West China School of Pharmacy, Sichuan University, Chengdu, People’s Republic of China; 4Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
Correspondence: Ting Xu
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China
Email tingx2009@163.com
Qiu Li
Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, People’s Republic of China
Email fbqiu9@163.com
Objective: The phase III POLO trial demonstrated that olaparib as maintenance therapy for metastatic pancreatic cancer patients with a germline BRCA mutation had greater efficacy than placebo, but maintenance olaparib places an economic burden on patients. This study evaluated the cost-effectiveness of olaparib as maintenance therapy based on the POLO trial (NCT02184195).
Methods: A three-state Markov model (progression-free survival [PFS], progressive disease [PD] and death) based on data from the POLO trial was used to estimate the incremental cost-effectiveness ratio (ICER) of maintenance olaparib versus placebo for metastatic pancreatic cancer patients with a germline BRCA mutation. The cost was evaluated from the Chinese society’s perspective, and health outcomes were assessed in terms of quality-adjusted life years (QALYs). The primary outcome was the ICER gained in terms of 2019 US$ per QALY. Model robustness was explored with one-way and probabilistic sensitivity analyses.
Results: Compared with placebo, maintenance olaparib increased costs by $23,544.35 while gaining 0.69 QALYs, resulting in an ICER of $34,122.25 per QALY. The ICER was far higher than the commonly accepted willingness-to-pay threshold ($28,255.55 per QALY).
Conclusion: Compared with placebo, maintenance olaparib for metastatic pancreatic cancer patients with a germline BRCA mutation is not cost-effective in China.
Keywords: cost effectiveness, pancreatic cancer, olaparib, BRCA, Markov model
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.